ADI vs NVDA

ADI's Piotroski F-Score of 4/9 indicates weak financial health, signaling potential distress in operational efficiency and capital structure. While the company exhibits strong profitability (23.02% net margin, 33.07% operating margin) and impressive revenue and earnings growth (30.4% and 116.7% YoY), its valuation is extremely stretched, trading at a forward P/E of 23.68 and current P/E of 55.85—well above sector averages. The Graham Number ($92.38) and intrinsic value ($161.66) suggest significant upside potential, but the current price of $306.07 reflects a premium driven by high growth expectations, not fundamental undervaluation. Insider selling activity over the past six months (13 transactions, $25.96M in sales) further undermines confidence in near-term prospects.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.